ISPC Stock Overview
Provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
iSpecimen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.45 |
| 52 Week High | US$12.59 |
| 52 Week Low | US$3.41 |
| Beta | 1.59 |
| 11 Month Change | -2.41% |
| 3 Month Change | -35.32% |
| 1 Year Change | -58.10% |
| 33 Year Change | -98.31% |
| 5 Year Change | n/a |
| Change since IPO | -96.89% |
Recent News & Updates
Recent updates
iSpecimen Inc. (NASDAQ:ISPC) Might Not Be As Mispriced As It Looks After Plunging 32%
Sep 13
US$3.00: That's What Analysts Think iSpecimen Inc. (NASDAQ:ISPC) Is Worth After Its Latest Results
Aug 09Take Care Before Diving Into The Deep End On iSpecimen Inc. (NASDAQ:ISPC)
Jan 04Downgrade: Here's How This Analyst Sees iSpecimen Inc. (NASDAQ:ISPC) Performing In The Near Term
Aug 07Investors Still Aren't Entirely Convinced By iSpecimen Inc.'s (NASDAQ:ISPC) Revenues Despite 33% Price Jump
Apr 18iSpecimen names finance chief Tracy Curley as interim CEO
Sep 22iSpecimen Inc. (NASDAQ:ISPC) Analysts Just Slashed This Year's Estimates
Aug 10iSpecimen GAAP EPS of -$0.30 misses by $0.02, revenue of $2.3M misses by $0.55M
Aug 04iSpecimen Inc.'s (NASDAQ:ISPC) Intrinsic Value Is Potentially 69% Above Its Share Price
Mar 31iSpecimen: High Growth Marketplace At A Discount
Jul 07iSpecimen raises $18M via Nasdaq IPO
Jun 21Shareholder Returns
| ISPC | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -0.7% | -10.1% | -2.1% |
| 1Y | -58.1% | 5.6% | 29.7% |
Return vs Industry: ISPC underperformed the US Healthcare Services industry which returned 5.6% over the past year.
Return vs Market: ISPC underperformed the US Market which returned 29.7% over the past year.
Price Volatility
| ISPC volatility | |
|---|---|
| ISPC Average Weekly Movement | 21.7% |
| Healthcare Services Industry Average Movement | 8.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ISPC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ISPC's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 53 | Tracy Curley | ispecimen.com |
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.
iSpecimen Inc. Fundamentals Summary
| ISPC fundamental statistics | |
|---|---|
| Market cap | US$2.79m |
| Earnings (TTM) | -US$9.52m |
| Revenue (TTM) | US$10.39m |
0.3x
P/S Ratio-0.3x
P/E RatioIs ISPC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISPC income statement (TTM) | |
|---|---|
| Revenue | US$10.39m |
| Cost of Revenue | US$5.41m |
| Gross Profit | US$4.98m |
| Other Expenses | US$14.51m |
| Earnings | -US$9.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.54 |
| Gross Margin | 47.98% |
| Net Profit Margin | -91.66% |
| Debt/Equity Ratio | 18.3% |
How did ISPC perform over the long term?
See historical performance and comparison